Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol in resectable pancreatic cancer
NCT03300921Phase 1Terminated
- Sponsor
- Abramson Cancer Center
- Start
- Sep 2017
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of paricalcitol oral solution in pancreatic cancer (PC) (2 arms), sponsored by Abramson Cancer Center. Primary endpoint: Number of Adverse Events at 18 months. Started Sep 2017; status: terminated.
02
Drugs
paricalcitol oral solution
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03300921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03300921.